المؤلفون: Marie José Kersten, Martin Dreyling, Kim M. Linton, Dana Chitu, Sanne Tonino, Marcel Kap, Roberto D Liu, Martine E.D. Chamuleau, Hein P.J. Visser, Eva De Jongh, Erik WAF Marijt, Maria B.L. Leijs, Yavuz M. Bilgin, Jan Dürig, Pamela McKay, Tjeerd J.F. Snijders, Andrew Pettitt, Monique C. Minnema, Gabriele Prange-Krex, Maria Cuijpers, Lara H. Böhmer, Lidwine W. Tick, Axel Florschütz, Matthijs Silbermann, Rob Fijnheer, Aart Beeker, Nelleke Tolboom, Cristina Mitea, Anne IJ Arens, Gerben JC Zwezerijnen, Wolfram Klapper, Sarah E. Coupland, Daphne de Jong, Jeanette K. Doorduijn, Josée M. Zijlstra

المصدر: Blood. 140:2283-2285

مصطلحات موضوعية: Immunology, Cell Biology, Hematology, Biochemistry

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::21c3544fd935fdd5132eebdec267e144
https://doi.org/10.1182/blood-2022-156085

المؤلفون: Coreline N. Burggraaff, Gregor Verhoef, Otto S. Hoekstra, Marie José Kersten, Lidwine W. Tick, Mels Hoogendoorn, Margreet Oosterveld, Daphne de Jong, Nicole C. H. P. van der Burg-de Graauw, Marinus van Marwijk Kooy, Matthijs H Silbermann, Aart Beeker, Marjolein van der Poel, Bart de Keizer, Eva de Jongh, Jeanette K. Doorduijn, Harry R. Koene, Thomas Stauffer Larsen, Memis Y Bilgin, Lara H Böhmer, Joost W. J. van Esser, Peter de Nully Brown, Marcel Nijland, Maria B.L. Leijs, J.F.M. Pruijt, Anne I.J. Arens, Josée M Zijlstra-Baalbergen, Pieternella J. Lugtenburg, Kon-Siong G. Jie, Rolf E. Brouwer, King H. Lam, Rob Fijnheer, Bronno van der Holt, Francesco d'Amore

المساهمون: RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Hematologie (9), Hematology, Health Technology Assessment (HTA), Pathology, Radiology & Nuclear Medicine, Radiotherapy, CCA - Cancer Treatment and Quality of Life, Clinical Haematology, Stem Cell Aging Leukemia and Lymphoma (SALL), Internal medicine, AGEM - Re-generation and cancer of the digestive system, CCA - Cancer Treatment and quality of life, Radiology and nuclear medicine

المصدر: Journal of Clinical Oncology, 38(29), 3377-3387. American Society of Clinical Oncology
Journal of Clinical Oncology, 38(29). American Society of Clinical Oncology
Lugtenburg, P J, De Nully Brown, P, Van der Holt, B, D'Amore, F A, Koene, H R, De Jongh, E, Fijnheer, R, Van Esser, J W, Bohmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, Van der Burg-De Graauw, N C, Oosterveld, M, Jie, K S G, Larsen, T S, Van der Poel, M W, Leijs, M B, Silbermann, M H, Van Marwijk Kooy, M, Beeker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, De Keizer, B, Arens, A I, De Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma : A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84) ', Journal of Clinical Oncology, vol. 38, no. 29, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418
Journal of clinical oncology, 38(29), 3377-3387. American Society of Clinical Oncology
Lugtenburg, P J, De Nully Brown, P, Van der Holt, B, D'Amore, F A, Koene, H R, De Jongh, E, Fijnheer, R, Van Esser, J W, Bohmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, Van der Burg-De Graauw, N C, Oosterveld, M, Jie, K S G, Larsen, T S, Van der Poel, M W, Leijs, M B, Silbermann, M H, Van Marwijk Kooy, M, Beeker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, De Keizer, B, Arens, A I, De Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-chop with early rituximab intensification for diffuse large b-cell lymphoma : A randomized phase iii trial of the hovon and the nordic lymphoma group (hovon-84) ', Journal of Clinical Oncology, vol. 38, no. 29, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418
Journal of Clinical Oncology, 38, 29, pp. 3377-3387
Journal of Clinical Oncology, 38(29), 3377-3387. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 38(29):38, 3377-3387. American Society of Clinical Oncology
Journal of Clinical Oncology, 38, 3377-3387
Lugtenburg, P J, de Nully Brown, P, van der Holt, B, D'Amore, F A, Koene, H R, de Jongh, E, Fijnheer, R, van Esser, J W, Böhmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, van der Burg-de Graauw, N C, Oosterveld, M, Jie, K-S G, Larsen, T S, van der Poel, M W, Leijs, M B, Silbermann, M H, van Marwijk Kooy, M, Beker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, de Keizer, B, Arens, A I, de Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84) ', Journal of Clinical Oncology, vol. 38, no. 29, 38, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418, https://doi.org/DOI: 10.1200/JCO.19.03418

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_treatment, CHOP, 0302 clinical medicine, Prednisone, Positron Emission Tomography Computed Tomography, Antineoplastic Combined Chemotherapy Protocols, Aged, 80 and over, response assessment, DOSE-DENSE RITUXIMAB, Induction Chemotherapy, Middle Aged, CHEMOTHERAPY, Treatment Outcome, 030220 oncology & carcinogenesis, Female, Rituximab, Lymphoma, Large B-Cell, Diffuse, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], medicine.drug, Adult, medicine.medical_specialty, Vincristine, DOXORUBICIN, Adolescent, Cyclophosphamide, plus cyclophosphamide, elderly-patients, vincristine, Maintenance Chemotherapy, Young Adult, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, Humans, non-hodgkin-lymphoma, OPTIMIZATION, Aged, Chemotherapy, business.industry, medicine.disease, Lymphoma, 030104 developmental biology, exposure, business, Diffuse large B-cell lymphoma, Follow-Up Studies

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c7540ecb6cafd809a54c75ab38ea46d
https://cris.maastrichtuniversity.nl/en/publications/14069863-94fd-45a6-a6a0-7e5cfcc2608a

المؤلفون: Michael Gregor, Florian Simon, Philipp B. Staber, Anna-Maria Fink, Christof Schneider, Vesa Lindström, Matthias Ritgen, Mels Hoogendoorn, Caspar da Cunha-Bang, Tamar Tadmor, Thomas Illmer, Maria B.L. Leijs, Arnon P. Kater, Nisha De Silva, Clemens-Martin Wendtner, Can Zhang, Julia von Tresckow, Marinus H. J. van Oers, Stephan Stilgenbauer, Henrik Frederiksen, Carsten Utoft Niemann, Moritz Fürstenau, Eugen Tausch, Michael Baumann, Sandra Robrecht, Christian Bjørn Poulsen, Ann Janssens, Holger Hebart, Monika Brüggemann, Gunnar Juliusson, Karl-Anton Kreuzer, Thomas Noesslinger, Tobias Gaska, Marjolein van der Klift, Christian H. Geisler, Kourosh Lotfi, Ilse Christiansen, Barbara Eichhorst, Björn Schöttker, Harry R. Koene, Mark-David Levin, Patrick Thornton, Michael Hallek, Kirsten Fischer, Ulrich Jaeger

المصدر: Eichhorst, B, Niemann, C U, Kater, A P, Fürstenau, M, Von Tresckow, J, Zhang, C, Robrecht, S, Gregor, M, Juliusson, G, Thornton, P, Staber, P B, Tadmor, T, Lindström, V, da Cunha-Bang, C, Schneider, C, Poulsen, C B, Thomas Illmer, T, Schöttker, B, Janssens, A, Christiansen, I, Noesslinger, T, Baumann, M, van der Klift, M, Jaeger, U J, Frederiksen, H, B.L. Leijs, M, Hoogendoorn, M, Lotfi, K, Hebart, H, Gaska, T, Koene, H R, Simon, F, De Silva, N, Fink, A-M, Fischer, K, Clemens-Martin Wendtner, Kreuzer, K-A, Ritgen, M, Brüggemann, M B, Tausch, E, Levin, M-D, van Oers, M H J, Geisler, C H, Stilgenbauer, S & Hallek, M 2021, ' A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial ', Blood, vol. 138, no. Supplement 1, pp. 71 . https://doi.org/10.1182/blood-2021-146161
Eichhorst, B, Niemann, C, Kater, A P, Fürstenau, M, Von Tresckow, J, Zhang, C, Robrecht, S, Gregor, M, Juliusson, G, Thornton, P, Staber, P B, Tadmor, T, Lindström, V, Da Cunha-Bang, C, Schneider, C, Poulsen, C B, Illmer, T, Schöttker, B, Janssens, A, Christiansen, I, Noesslinger, T, Baumann, M, van der Klift, M, Jaeger, U, Frederiksen, H, Leijs, M B L, Hoogendoorn, M, Lotfi, K, Hebart, H, Gaska, T, Koene, H R, Simon, F, De Silva, N, Fink, A-M, Fischer, K, Wendtner, C-M, Kreuzer, K-A, Ritgen, M, Brüggemann, M, Tausch, E, Levin, M-D, Van Oers, M H J, Geisler, C H, Stilgenbauer, S & Hallek, M 2021, ' A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial ', Blood, vol. 138, no. Suppl. 1, 71 . https://doi.org/10.1182/blood-2021-146161

مصطلحات موضوعية: Oncology, 0303 health sciences, medicine.medical_specialty, business.industry, Venetoclax, Chronic lymphocytic leukemia, Immunology, Cell Biology, Hematology, medicine.disease, Biochemistry, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, chemistry, Chemoimmunotherapy, Internal medicine, Clinical endpoint, Medicine, business, 030304 developmental biology, 030215 immunology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46700f17dedbd3070657cd5923f53a3a
https://portal.findresearcher.sdu.dk/da/publications/fca2ae81-daf7-4cd6-8e83-f4a2a71437b8

المؤلفون: Kaz Groen, Maria B.L. Leijs, Ellen van der Spek, Esther G.M. De Waal, Pieter Sonneveld, Maarten R. Seefat, Mark-David Levin, Inger S. Nijhof, Lidwine W. Tick, Matthijs Westerman, Saskia K. Klein, Maaike Sohne, Gert-Jan Timmers, Fransien Croon-de Boer, Marie-Christiane Vekemans, Roel J.W. van Kampen, Claudia A.M. Stege, Inge Ludwig, Ka Lung Wu, Gerjo A. Velders, Sonja Zweegman, Kazem Nasserinejad, Noortje Thielen, Paula F. Ypma, Niels W.C.J. van de Donk, Koen de Heer, Djamila E. Issa

المصدر: Blood. 138:80-80

مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, Immunology, Low dose, Daratumumab, Cell Biology, Hematology, Newly diagnosed, medicine.disease, Biochemistry, Ixazomib, chemistry.chemical_compound, chemistry, Internal medicine, medicine, business, Multiple myeloma, Dexamethasone, INDUCTION TREATMENT, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::f7ce0479071e13b20957f5600fc2773c
https://doi.org/10.1182/blood-2021-152112

المؤلفون: Maria B.L. Leijs, Pieter Sonneveld, Bronno van der Holt, Marian Stevens-Kroef, Per Axelsson, Niels Abildgaard, Markus Hansson, Pino Poddighe, Saskia K. Klein, Anders Waage, Sonja Zweegman, Dorota Knut-Bojanovska, Asta Svirskaite, Einar Haukås, Mark-David Levin, Fredrik Schjesvold, Damian L. Szatkowski, Niels W.C.J. van de Donk, Trung Hieu Do, Claudia A.M. Stege, Ellen van der Spek

المصدر: Zweegman, S, Schjesvold, F H, van der Holt, B, Levin, M-D, Stege, C A M, Waage, A, Leijs, M B L, Klein, S K, Szatkowski, D L, Axelsson, P, Do, T H, Knut-Bojanovska, D, van der Spek, E, Svirskaite, A, Poddighe, P, Stevens-Kroef, M, Hansson, M, van de Donk, N W C J, Haukas, E, Sonneveld, P & Abildgaard, N 2018, ' Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Results from the Randomized Phase II HOVON-126/Nmsg 2113 Trial ', Blood, vol. 132, no. Suppl. 1 . https://doi.org/10.1182/blood-2018-99-111650
Zweegman, S, Schjesvold, F H, van der Holt, B, Levin, M-D, Stege, C A M, Waage, A, Leijs, M B L, Klein, S K, Szatkowski, D L, Axelsson, P, Do, T H, Knut-Bojanovska, D, van der Spek, E, Svirskaite, A, Poddighe, P, Stevens-Kroef, M, Hansson, M, van de Donk, N W C J, Haukas, E, Sonneveld, P & Abildgaard, N 2018, ' Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Results from the Randomized Phase II HOVON-126/Nmsg 21#13 Trial ', Blood, vol. 132, no. Suppl. 1, pp. 800-800 . https://doi.org/10.1182/blood-2018-99-111650

مصطلحات موضوعية: medicine.medical_specialty, Randomization, business.industry, Immunology, Cell Biology, Hematology, Placebo, Biochemistry, Ixazomib, Thalidomide, Transplantation, 03 medical and health sciences, Regimen, chemistry.chemical_compound, 0302 clinical medicine, chemistry, Maintenance therapy, 030220 oncology & carcinogenesis, Internal medicine, medicine, Progression-free survival, business, 030215 immunology, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ceeda16a8771971fe347d1cbf1046e5
https://portal.findresearcher.sdu.dk/da/publications/e77b2b7e-45e9-46e3-8538-b5ea1c4d970d

المؤلفون: Maria B.L. Leijs, Sonja Zweegman, Nazik Durdu-Rayman, Alain Kentos, Saskia K. Klein, Nicole C. H. P. van der Burg-de Graauw, Niels W.C.J. van de Donk, Roel J. W. van Kampen, Noortje Thielen, Koen de Heer, Mark-David Levin, Esther G. M. de Waal, Kazem Nasserinejad, Pieter Sonneveld, Ellen van der Spek, Gert Jan Timmers, Claudia A.M. Stege, Inge Ludwig, Matthijs Westerman, Maaike Sohne, Marie Christiane Vekemans, Yavuz M. Bilgin

المصدر: Blood. 134:695-695

مصطلحات موضوعية: medicine.medical_specialty, business.industry, Influenzavirus B, Mortality rate, Immunology, Cell Biology, Hematology, Biochemistry, Sudden death, Discontinuation, Transplantation, Regimen, Tolerability, Maintenance therapy, Internal medicine, Medicine, business, health care economics and organizations

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::bc4b59cccb98eeb243ce00168f2b7dc9
https://doi.org/10.1182/blood-2019-121694